【康希诺生物：破伤风疫苗获国家药监局NDA批准，III期临床免疫原性优于对照疫苗】康希诺生物公告，公司研发的吸附破伤风疫苗已获得中国国家药品监督管理局的新药上市申请批准。该疫苗采用无动物源培养基发酵，主要用于非新生儿破伤风预防，III期临床数据显示免后30天抗体GMC优于对照疫苗，具有明显免疫原性优势。公司已与远大生命科学集团就该疫苗达成独家商业化合作协议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.